Phase III Trial: Bone and Renal Effects With Denosumab vs Zoledronic Acid in Newly Diagnosed MM

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
Results of this large international phase III trial showed that denosumab was associated with significantly less renal toxicity and prolonged PFS vs zoledronic acid in patients with newly diagnosed MM.
Format: Microsoft PowerPoint (.ppt)
File Size: 545 KB
Released: June 14, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings